Increasing Transparency in Generic Drug Applications Act

S 1302, the "Increasing Transparency in Generic Drug Applications Act," requires the FDA to disclose to generic drug applicants whether their proposed drug matches the brand-name reference drug in inactive ingredients (type and amount). If differences exist, the FDA must specify which ingredients differ and the exact quantitative deviations. The bill mandates the FDA issue guidance within one year on how it determines ingredient similarity, including for pH adjusters, after a 60-day public comment period. This directly affects generic drug manufacturers seeking FDA approval by providing clearer, earlier feedback during the application review process.